Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2

被引：54

作者：

Zak, Mark ^{[1
]}

Mendonca, Rohan ^{[1
]}

Balazs, Mercedesz ^{[8
]}

Barrett, Kathy ^{[2
]}

Bergeron, Philippe ^{[1
]}

Blair, Wade S. ^{[2
]}

Chang, Christine ^{[2
]}

Deshmukh, Gauri ^{[3
]}

DeVoss, Jason ^{[8
]}

Dragovich, Peter S. ^{[1
]}

Eigenbrot, Charles ^{[7
]}

Ghilardi, Nico ^{[4
]}

Gibbons, Paul ^{[1
]}

Gradl, Stefan ^{[1
]}

Hamman, Chris ^{[1
]}

Hanan, Emily J. ^{[1
]}

Harstad, Eric ^{[5
]}

Hewitt, Peter R. ^{[9
]}

Hurley, Christopher A. ^{[9
]}

Jin, Tian ^{[10
]}

Johnson, Adam ^{[2
]}

Johnson, Tony ^{[9
]}

Kenny, Jane R. ^{[3
]}

Koehler, Michael F. T. ^{[1
]}

Kohli, Pawan Bir ^{[2
]}

Kulagowski, Janusz J. ^{[9
]}

Labadie, Sharada ^{[1
]}

Liao, Jiangpeng ^{[10
]}

Liimatta, Marya ^{[2
]}

Lin, Zhonghua ^{[8
]}

Lupardus, Patrick J. ^{[7
]}

Maxey, Robert J. ^{[9
]}

Murray, Jeremy M. ^{[7
]}

Pulk, Rebecca ^{[1
]}

Rodriguez, Madeleine ^{[8
]}

Savage, Scott ^{[6
]}

Shia, Steven ^{[7
]}

Steffek, Micah ^{[7
]}

Ubhayakar, Savita ^{[3
]}

Ultsch, Mark ^{[7
]}

van Abbema, Anne ^{[2
]}

Ward, Stuart I. ^{[9
]}

Xiao, Ling ^{[10
]}

Xiao, Yisong ^{[10
]}

机构：

[1] Genentech Inc, Dept Discovery Chem, San Francisco, CA 94080 USA

[2] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA

[3] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA

[5] Genentech Inc, Dept Safety Assessment, San Francisco, CA 94080 USA

[6] Genentech Inc, Dept Small Mol Proc Chem, San Francisco, CA 94080 USA

[7] Genentech Inc, Dept Biol Struct, San Francisco, CA 94080 USA

[8] Genentech Inc, Dept Translat Immunol, San Francisco, CA 94080 USA

[9] Argenta, Spire Green Ctr 8 9, Harlow CM19 5TR, Essex, England

[10] WuXi AppTec Co Ltd, Shanghai 200131, Peoples R China

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2012年 / 55卷 / 13期

关键词：

JANUS KINASE; RHEUMATOID-ARTHRITIS; SIGNAL-TRANSDUCTION; RECEPTOR; ERYTHROPOIETIN; ACTIVATION; CP-690,550; STATS; INCB018424; PREDICTION;

D O I：

10.1021/jm300628c

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochemical and cell-based assays, respectively). Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated. Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20). Details of the biological characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.

引用

页码：6176 / 6193

页数：18

共 50 条

[1] Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
Zak, Mark
Hurley, Christopher A.
Ward, Stuart I.
Bergeron, Philippe
Barrett, Kathy
Balazs, Mercedesz
Blair, Wade S.
Bull, Richard
Chakravarty, Paroma
Chang, Christine
Crackett, Peter
Deshmukh, Gauri
DeVoss, Jason
Dragovich, Peter S.
Eigenbrot, Charles
Ellwood, Charles
Gaines, Simon
Ghilardi, Nico
Gibbons, Paul
Gradl, Stefan
Gribling, Peter
Hamman, Chris
Harstad, Eric
Hewitt, Peter
Johnson, Adam
Johnson, Tony
Kenny, Jane R.
Koehler, Michael F. T.
Kohli, Pawan Bir
Labadie, Sharada
Lee, Wyne P.
Liao, Jiangpeng
Liimatta, Marya
Mendonca, Rohan
Narukulla, Raman
Pulk, Rebecca
Reeve, Austin
Savage, Scott
Shia, Steven
Steffek, Micah
Ubhayakar, Savita
van Abbema, Anne
Aliagas, Ignacio
Avitabile-Woo, Barbara
Xiao, Yisong
Yang, Jing
Kulagowski, Janusz J.
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) : 4764 - 4785
[2] Discovery and optimization of potent, selective, and orally bioavailable Jak1 inhibitors
Zak, Mark
Johnson, Adam
Van Abbema, Anne
Waszkowycz, Bohdan
Eigenbrot, Charles
Chang, Christine
Hurley, Christopher
Hanan, Emily
Kenny, Jane
Kulagowski, Janusz
DeVoss, Jason
Murray, Jeremy
Balazs, Mercedesz
Steffek, Micah
Koehler, Michael
Ghilardi, Nico
Chakravarty, Paroma
Lupardus, Patrick
Gibbons, Paul
Dragovich, Peter
Bergeron, Philippe
Pulk, Rebecca
Mendonca, Rohan
Savage, Scott
Labadie, Sharada
Gradl, Stefan
Ward, Stuart
Blair, Wade
Jia, Wei
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[3] Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2
Labadie, Sharada S.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
[4] Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2
Labadie, Sharada
Dragovich, Peter S.
Barrett, Kathy
Blair, Wade S.
Bergeron, Philippe
Chang, Christine
Deshmukh, Gauri
Eigenbrot, Charles
Ghilardi, Nico
Gibbons, Paul
Hurley, Christopher A.
Johnson, Adam
Kenny, Jane R.
Kohli, Pawan Bir
Kulagowski, Janusz J.
Liimatta, Marya
Lupardus, Patrick J.
Mendonca, Rohan
Murray, Jeremy M.
Pulk, Rebecca
Shia, Steven
Steffek, Micah
Ubhayakar, Savita
Ultsch, Mark
van Abbema, Anne
Ward, Stuart
Zak, Mark
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (24) : 7627 - 7633
[5] Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2
Xu, Pengfei
Shen, Pei
Wang, Hai
Qin, Lian
Ren, Jie
Sun, Qiushuang
Ge, Raoling
Bian, Jinlei
Zhong, Yi
Li, Zhiyu
Wang, JuBo
Qiu, Zhixia
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 218
[6] Discovery of CYT387: A potent and selective dual inhibitor of JAK1 and JAK2
Burns, Christopher J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[7] Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors
Su, Qibin
Ioannidis, Stephanos
Chuaqui, Claudio
Almeida, Lynsie
Alimzhanov, Marat
Bebernitz, Geraldine
Bell, Kirsten
Block, Michael
Howard, Tina
Huang, Shan
Huszar, Dennis
Read, Jon A.
Costa, Caroline Rivard
Shi, Jie
Su, Mei
Ye, Minwei
Zinda, Michael
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (01) : 144 - 158
[8] Prevention of Islet Inflammatory Stress with JAK1/JAK2 Inhibitors
Watson, Eleanor
Waibel, Michaela
Trivedi, Prerak
Pappas, Evan
Fynch, Stacey
Sutherland, Robyn
Kay, Thomas
Thomas, Helen
TRANSPLANTATION, 2018, 102 : S370 - S370
[9] Discovery of INCB018424: A potent and selective JAK1/JAK2 inhibitor for the treatment of myeloproliferative neoplasms
Rodgers, James D.
Fridman, Jordan S.
Shepard, S.
Maduskuie, T. P.
Arvanitis, A. G.
Wang, H.
Shao, L.
Folmer, B.
Falahatpisheh, N.
Rafalski, M.
Storace, L.
Jalluri, R. K.
Vaddi, K.
Haley, P. J.
Burn, T. C.
Rupar, M.
Liu, P. C.
Covington, M. B.
Caulder, E.
Li, J.
Waeltz, P.
Margulis, A.
Wynn, R.
Becker-Pasha, M.
Li, Y.
Lo, Y.
Thomas, B.
Hollis, G.
Favata, M. F.
Wen, X.
Kelly, J.
Solomon, K.
Scherle, P. A.
Shi, J.
Yeleswaram, S.
Newton, R. C.
Friedman, S. M.
Metcalf, B.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[10] Discovery of polycyclic azaindoles and deazapurines as potent JAK2 inhibitors
Ledeboer, Mark W.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240

← 1 2 3 4 5 →